Advertisement

Topics

Priority Review Granted for Gilead Fixed-Dose HIV Combination Treatment

06:10 EDT 11 Aug 2017 | PharmPro

Gilead announces U.S. FDA priority review designation for fixed-dose combination of bictegravir, emtricitabine, and tenofovir alafenamide for treatment of HIV. Final FDA decision is anticipated by February 12, 2018.
Contributed Author: 
Gilead Sciences, Inc.

Original Article: Priority Review Granted for Gilead Fixed-Dose HIV Combination Treatment

NEXT ARTICLE

More From BioPortfolio on "Priority Review Granted for Gilead Fixed-Dose HIV Combination Treatment"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...